Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation.

Chemokines regulate the trafficking of leukocytes in immunity and inflammation and have been implicated in mouse models in acute cardiac and renal allograft rejection; however, their significance to human transplantation is not yet defined. The association of human chemokine receptor genetic variants, CCR5-Delta32, CCR5-59029-A/G, CCR2-V64I, CX3CR1-V249I, and CX3CR1-T280M, with outcome in 163 renal transplant recipients was examined here. Significant reductions were found in risk of acute renal transplant rejection in recipients who possessed the CCR2-64I allele (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.12 to 0.78; P = 0.014) or who were homozygous for the 59029-A allele (OR, 0.37; 95% CI, 0.16 to 0.85; P = 0.016). There were no significant differences in the incidence of rejection among patients stratified as with or without CCR5-Delta32 or by the CX3CR1-V249I or CX3CR1-T280M genotypes. Adjustment for known risk factors for transplant rejection confirmed the univariate findings for possession of the CCR2-64I allele (OR, 0.20; P = 0.032) and homozygosity for the 59029-A allele (OR, 0.26; P = 0.027). It was concluded that the risk of acute rejection in renal transplantation is associated with genetic variation in the chemokine receptors CCR2 and CCR5.

[1]  W. Hancock,et al.  Chemokines and transplant immunobiology. , 2002, Journal of the American Society of Nephrology : JASN.

[2]  J. Sullivan.  CC chemokine receptor 5 and renal-transplant survival , 2001, The Lancet.

[3]  A. Quyyumi,et al.  Association Between Polymorphism in the Chemokine Receptor CX3CR1 and Coronary Vascular Endothelial Dysfunction and Atherosclerosis , 2001, Circulation research.

[4]  Klemens Budde,et al.  CC chemokine receptor 5 and renal-transplant survival , 2001, The Lancet.

[5]  C. Alpers,et al.  Expression of chemokines and chemokine receptors during human renal transplant rejection. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  M. Kamoun,et al.  Cellular and molecular parameters in human renal allograft rejection. , 2001, Clinical biochemistry.

[7]  J. Goedert,et al.  Genetic polymorphism in CX3CR1 and risk of HIV disease. , 2000, Science.

[8]  D. Patel,et al.  A Role for Fractalkine and Its Receptor (CX3CR1) in Cardiac Allograft Rejection1 , 2000, The Journal of Immunology.

[9]  H. Weiner,et al.  Resistance to Experimental Autoimmune Encephalomyelitis in Mice Lacking the Cc Chemokine Receptor (Ccr2) , 2000, The Journal of experimental medicine.

[10]  W. Hancock,et al.  Chemokines and their receptors in allograft rejection. , 2000, Current opinion in immunology.

[11]  W. Kuziel,et al.  Cc Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune Encephalomyelitis , 2000, The Journal of experimental medicine.

[12]  Y. Yan,et al.  Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. , 2000, International immunology.

[13]  E. Génin,et al.  Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. , 2000, Science.

[14]  K. Matsushima,et al.  International union of pharmacology. XXII. Nomenclature for chemokine receptors. , 2000, Pharmacological reviews.

[15]  A. Morley,et al.  Renal allograft rejection: beta-chemokine involvement in the development of tubulitis. , 2000, Transplantation.

[16]  C. Weber,et al.  Met‐RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[18]  J. Goedert,et al.  Genetic acceleration of AIDS progression by a promoter variant of CCR5. , 1998, Science.

[19]  C. Kleeberger,et al.  CCR5 promoter polymorphism and HIV-1 disease progression , 1998, The Lancet.

[20]  J J Goedert,et al.  Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. , 1997, Science.

[21]  Nancy Sullivan,et al.  CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro , 1997, The Journal of experimental medicine.

[22]  L. Gesualdo,et al.  Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. , 1997, Transplantation.

[23]  D. Weissman,et al.  Inherited Resistance to HIV-1 Conferred by an Inactivating Mutation in CC Chemokine Receptor 5: Studies in Populations with Contrasting Clinical Phenotypes, Defined Racial Background, and Quantified Risk , 1997, Molecular medicine.

[24]  B. Brenner,et al.  Antigen-independent determinants of cadaveric kidney transplant failure. , 1996, JAMA.

[25]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[26]  E. Milford.  Chronic renal allograft loss. , 1994, Current opinion in nephrology and hypertension.

[27]  M. Polley.  Renal transplantation. , 1967, Nursing times.